We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+3.41%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$118M
AUM Growth
-$12M
Cap. Flow
-$24.6M
Cap. Flow %
-20.81%
Top 10 Hldgs %
43.16%
Holding
94
New
22
Increased
10
Reduced
13
Closed
18

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$7.61M
2
XNPT
XENOPORT, INC.
XNPT
+$2.71M
3
ACHN
Achillion Pharmaceuticals
ACHN
+$2.26M
4
OTIC
Otonomy, Inc.
OTIC
+$1.72M
5
CYAD
Celyad Oncology SA American Depositary Shares
CYAD
+$1.61M

Top Sells

Rank Stock Value
1
PCYC
PHARMACYCLICS INC
PCYC
+$18.3M
2
ASPX
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
+$12.1M
3
MTEM
Molecular Templates, Inc.
MTEM
+$2.54M
4
ATRC icon
AtriCure
ATRC
+$1.98M
5
CRIS icon
Curis
CRIS
+$720K

Sector Composition

Rank Sector Weight
1 Healthcare 72.51%
2 Financials 0.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZGNX
26
DELISTED
Zogenix, Inc.
ZGNX
$1.43M 1.21%
106,713
– –
SCYX icon
27
SCYNEXIS
SCYX
$36M
$1.42M 1.2%
+2,017
New +$1.45M
GYRE icon
28
Gyre Therapeutics
GYRE
$668M
$1.29M 1.09%
589
-2
-0.3% -$4.01K
NVDQ
29
DELISTED
Novadaq Technologies Inc.
NVDQ
$1.23M 1.04%
101,841
– –
DRNA
30
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$1.21M 1.02%
+86,800
New +$1.59M
CYTR
31
DELISTED
CytRx Corp
CYTR
$1.12M 0.95%
50,136
– –
QURE icon
32
uniQure
QURE
$2.52B
$1.08M 0.91%
40,000
+10,000
+33% +$285K
BLUE
33
DELISTED
bluebird bio
BLUE
$1.01M 0.85%
463
-155
-25% -$316K
DERM
34
DELISTED
Dermira, Inc.
DERM
$996K 0.84%
+56,736
New +$875K
ELOS
35
DELISTED
Syneron Medical Ltd
ELOS
$966K 0.82%
90,947
– –
CDNA icon
36
CareDx
CDNA
$1.85B
$947K 0.8%
145,627
+21,744
+18% +$118K
JNJ icon
37
Johnson & Johnson
JNJ
$643B
$916K 0.77%
9,400
– –
SPNC
38
DELISTED
Spectranetics Corp
SPNC
$916K 0.77%
39,812
– –
ARNA
39
DELISTED
Arena Pharmaceuticals Inc
ARNA
$877K 0.74%
+18,900
New +$820K
CRDC
40
DELISTED
CARDICA INC COM NEW (DE)
CRDC
$742K 0.63%
148,600
– –
LPCN icon
41
Lipocine
LPCN
$17.6M
$729K 0.62%
+5,000
New +$621K
EXAC
42
DELISTED
Exactech Inc
EXAC
$659K 0.56%
31,636
– –
ORKA
43
Oruka Therapeutics
ORKA
$5.46B
$653K 0.55%
+376
New +$494K
ECI
44
DELISTED
ENCISION INC
ECI
$584K 0.49%
1,062,500
– –
CGNT
45
DELISTED
Cogentix Medical, Inc.
CGNT
$572K 0.48%
+353,181
New +$578K
SRGA
46
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$555K 0.47%
2,864
– –
ICPT
47
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$483K 0.41%
2,000
– –
LMNS
48
DELISTED
LUMENIS LTD CL B ORD SHS (ISR)
LMNS
$426K 0.36%
31,072
– –
AFMD
49
DELISTED
Affimed
AFMD
$390K 0.33%
2,895
-3,355
-54% -$322K
TNDM icon
50
Tandem Diabetes Care
TNDM
$1.22B
$390K 0.33%
3,599
-4,035
-53% -$502K
1
2
3 4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
STCG
Speece Thorson Capital Group Minnetonka, Minnesota $439M AUM 10.15% 1-Year Est. Return
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
CPW
Cove Private Wealth Oyster Bay Cove, New York $440M AUM 27.56% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
DWML
Decker Wealth Management LLC Nashville, Tennessee $441M AUM

DAFNA Capital Management's Q2 2015 Portfolio in Review

As of Q2 2015, DAFNA Capital Management held 94 positions worth $118M, down 9.2% from $130M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

DAFNA Capital Management withdrew a net $24.6M in Q2 2015, closing 18 positions and reducing 13 holdings. Its most notable exit was PHARMACYCLICS INC, an estimated $18.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets, up from 56% a quarter earlier, followed by Financials.

Against the trend, DAFNA Capital Management opened a new position in AbbVie worth $7.83M.

  • DAFNA Capital Management's largest Q2 2015 buy was AbbVie: 116,581 shares worth $7.83M.
  • DAFNA Capital Management added most to XENOPORT, INC. in Q2 2015, an estimated $2.71M increase.
  • DAFNA Capital Management's biggest Q2 2015 reduction was AtriCure, cutting an estimated $1.98M.
  • DAFNA Capital Management fully exited PHARMACYCLICS INC in Q2 2015, selling an estimated $18.3M.
  • DAFNA Capital Management's ten largest holdings make up 43% of its $118M portfolio in Q2 2015.
  • DAFNA Capital Management opened 22 new positions and closed 18 in Q2 2015.
  • DAFNA Capital Management's portfolio value fell 9.2% quarter-over-quarter to $118M.

Based on DAFNA Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.